Nancy Nagle, MD
Pulmonary Disease · Okc, OKNPI 1740245745
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,400 of the $51,284 with a category attached, or 84.6%. AstraZeneca accounts for 90.0% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $25,645, 8.3 times the $3,093 reported in 2019. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $121.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$46K
- Boehringer Ingelheim$920
- GSK$700
- Sunovion Pharmaceuticals Inc.$515
- Genentech USA, Inc.$448
- Philips North America LLC$258
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$43,40085%
- Travel & lodging$9622%
- Food & beverage$6,92213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 74 | $46,135 |
| Boehringer Ingelheim | 56 | $920 |
| GSK | 56 | $700 |
| Sunovion Pharmaceuticals Inc. | 50 | $515 |
| Genentech USA, Inc. | 30 | $448 |
| Philips North America LLC | 20 | $258 |
| Grifols USA, LLC | 14 | $249 |
| Fisher & Paykel Healthcare Inc | 4 | $223 |
| Teva Pharmaceuticals USA, Inc. | 21 | $190 |
| Mylan Specialty L.p. | 14 | $171 |
| Sanofi | 8 | $170 |
| Shire North American Group Inc | 11 | $168 |
| Regeneron Healthcare Solutions, Inc. | 7 | $134 |
| Sanofi-aventis U.S. LLC | 6 | $118 |
| Circassia Inc. | 6 | $85 |
| Advanced Respiratory, Inc | 4 | $84 |
| Gilead | 4 | $81 |
| Insmed, Inc. | 4 | $80 |
| Johnson & Johnson | 5 | $71 |
| Novartis | 3 | $62 |
| Merck | 4 | $58 |
| Electromed, Inc. | 5 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Portola Pharmaceuticals, LLC | 1 | $49 |
| Pfizer | 4 | $48 |
| United Therapeutics Corporation | 2 | $37 |
| Optinose US, Inc. | 2 | $29 |
| La Jolla Pharmaceutical Company | 2 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$45,063
- SYMBICORT$455
- FASENRA$455
- IMFINZI$244
- BREZTRI AEROSPHERE$211
How this compares
$51,284 in reported general payments places this provider in the 90th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Okc
- Dennis ParkerOkc$46K
- Michael HullEdmond$642K
- John KingreyOklahoma City$332K
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Grace KennedyTulsa$57K
- Walter BoomerTulsa$43K
- Nathaniel MoultonOklahoma City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.